Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Cost Of Early Progression: Patients With Epidermal Growth Factor Receptor Mutated Metastatic Non-small-cell Lung Cancer

Cost of early progression: patients with epidermal growth factor receptor mutated metastatic non-small-cell lung cancer

Nicole Princic1, Elizabeth Marrett2, Winghan Jacqueline Kwong2

  • 1Merative, Ann Arbor, MI 48103, USA.

Future Oncology (London, England)
|July 16, 2024

Related Experiment Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.9K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.1K

View abstract on PubMed

Summary
This summary is machine-generated.

Progression in epidermal growth factor receptor mutated metastatic non-small-cell lung cancer (EGFRm mNSCLC) significantly increases healthcare costs. Early progression leads to higher medical expenses compared to later progression, impacting overall patient care budgets.

Area of Science:

  • Oncology
  • Health Economics

Background:

  • Epidermal growth factor receptor mutated (EGFRm) metastatic non-small-cell lung cancer (mNSCLC) requires ongoing management.
  • Understanding healthcare costs associated with disease progression is crucial for resource allocation.

Purpose of the Study:

  • To compare healthcare costs in patients with EGFRm mNSCLC with and without disease progression.
  • To estimate the economic impact of disease progression, differentiating between early and late progression.

Main Methods:

  • Retrospective analysis of adult patient claims data from 2015-2020.
  • Inclusion of patients with EGFRm mNSCLC initiating EGFR tyrosine kinase inhibitors.
  • Comparison of 12-month adjusted costs and prediction of 36-month cumulative costs based on progression timing.
Keywords:
epidermal growth factor activating mutationhealthcare costslung cancerprogression

Related Experiment Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.9K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.1K

Main Results:

  • A total of 228 patients were analyzed.
  • Patients experiencing progression within 12 months had significantly higher total healthcare costs, despite lower treatment expenses.
  • Early progressors incurred substantially higher medical costs than late progressors.

Conclusions:

  • Disease progression in EGFRm mNSCLC is associated with increased healthcare expenditures.
  • Identifying the timing of progression is key to understanding cost drivers.
  • These findings can assist healthcare providers in delivering cost-efficient, high-quality care.
tyrosine kinase inhibitors